Table 5 Treatment after interruption due to AST and/or ALT elevation with a CTCAE grade ≥2.

From: Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis

 

n

Resume at a reduced dose of 100 mg twice daily

10

   Continue

6

   Re-interrupt

4

      recurrence of AST/ALT elevation with CTCAE grade ≥2

2

      nausea

1

      fever

1

Discontinue without resumption

6

      patient rejection

2

      acute hypochondriac pain

2

      deterioration of physical condition

1

      eosinophilia in peripheral blood

1

  1. Abbreviations; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CTCAE = Common Terminology Criteria for Adverse Events.
Back to article page